Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications

Very limited labelled indications have been approved for the newer antimicrobials. Data on the clinical uses, efficacy and safety of dalbavancin are scarce, thus here we sought to describe our clinical experience. 16-month observational prospective study was performed. 19 (86%) were used under off-l...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Eur J Hosp Pharm
Main Authors: Núñez-Núñez, María, Casas-Hidalgo, Inmaculada, García-Fumero, Ricardo, Vallejo-Rodríguez, Inmaculada, Anguita-Santos, Francisco, Hernández-Quero, José, Cabeza-Barrera, José, Ruiz-Sancho, Andrés
Format: Artigo
Sprog:Inglês
Udgivet: BMJ Publishing Group 2020
Fag:
Short Report
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7447242/
https://ncbi.nlm.nih.gov/pubmed/32839266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-001711
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker